

*

/ / : / / :

Comparison of anti-inflammatory and anti-leukocyte accumulation effects of statins

Andalib S.¹, Ziae M.¹, Maleki N.¹, Maljaei H.², Hamzeiy H.¹, Garjani A.^{*3}


¹ School of Pharmacy, Tabriz University of Medical Sciences, ² School of Medicine, Tabriz University of Medical Sciences,

³Research Center of Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences


Received: 2007/4/18 , Accepted: 2007/8/14

Objectives: Statins have been proven to possess anti-inflammatory activities unrelated to cholesterol lowering actions. Here we compared the anti-inflammatory and anti-leukocyte accumulation effects of atorvastatin, simvastatin and lovastatin. **Methods:** Carrageenan-induced rat paw edema and mouse air-pouch as acute and local inflammatory models were used in this study. Animals were received 1, 5, and 10 mg/kg of drugs orally 20, 12, 6, and 1h prior to inflammation induction by injection of carrageenan into either rat paw or the pouch. **Results:** We found that all three statins reduced both the maximal edema response attained during 4h and neutrophils infiltration in inflammation zone. Lovastatin had the lowest and atorvastatin had the greatest effects. The effect of simvastatin was between lovastatin and atorvastatin. During this time statins did not alter serum cholesterol and triglycerides. Atorvastatin (10 mg/kg) caused the most potent inhibition of the carrageenan-induced inflammation (70% reduction; p<0.0001) and leukocyte accumulation (80% reduction; p<0.0001). Atorvastatin was comparable to indomethacin in this model. Also, in the mouse air-pouch model atorvastatin treatment produced a very significant (p<0.0001) reduction in carrageenan-induced pouch leukocyte recruitment and exudates production. Co-administration of mevalonate reversed the effect of atorvastatin on leukocyte recruitment and the exudates production. **Conclusion:** The result of this study shows that the anti-inflammatory potency of statins is according to their inhibitory potency on hydroxy-methyl-glutaryl CoA reductase but unrelated to lipid reduction.

Key words: Statins, Atorvastatin, anti-inflammatory, carrageenan.






*Corresponding Author: Dr Alireza Garjani, Professor, Research Center of Pharmaceutical Nanotechnology; Tabriz University of Medical Sciences, Tel: 0411-3341315; Fax: 0411-3344798; E-mail: garjania@tbzmed.ac.ir





$(p < 0.001)$




***p<0.001 **p<0.01 .

Mean+-SD

()

()

ANOVA




(AUC)

.Student's t test

()

***p<0.0001 **p<0.001

Mean+SD




mg/kg

()

()


()

()




***p<0.0001 **p<0.001 .Mean±SD (PMN)

.Student's t test



***p<0.0001 **p<0.001 .

.Student's t test



6- References:

1. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. *BMJ*, 2003, 326:1423.
2. M. Weis S., Whihney E., Shapiro D.R., Beere PA., Langendorfer A., Stein EA., Kruyer W., Gotto AM. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. *The Journal of the American Medical Association (JAMA)*, 1998, 279: 1615-1622.
3. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., Flaker G.C., Braunwald E. Pravastatin and risk of coronary events after myocardial infarction in patients with average cholesterol levels. *Circulation*, 1998, 98: 839-844.
4. Steinberg D. Hypercholesterolemia and inflammation in atherogenesis: two sides of the same coin, *Mol. Nutr. Food Res.*, 2005 Nov, 49(11): 995-8.
5. Smith G., Davidson R., Bloor S. Pharmacological properties of ZD4522-a new HMG-CoA reductase inhibitor [Poster], Presented at the International Symposium on Atherosclerosis, Stockholm, 2000 June 25-29.
6. Arnaud C., Braunersreuther V., Mach F. Toward immunomodulatory and anti inflammatory properties of statins, *Trends Cardiovasc. Med.*, 2005 Aug, 15(6): 202-6.
7. Coward WR., Marei A., Yang A., Vesa-Nicotera MM., Chow SC. Statin-induced proinflammatory response in mitogen- activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes, *J Immunol.*, 2006 May, 176(9): 5284-92.
8. Casey P.J. Protein lipidation in cell signaling, *Science*, 1995, 268: 221-225.
9. Maleki N., Garjani A., Nazemiyeh H., Nilforoushan N., Eftekhar Sadat AT., Allameh Z., Hasannia N. Potent Anti-Inflammatory of Hydroalcoholic Extract from Aerial Parts of Stachys Inflata on Rats, *Journal of Ethnopharmacology*, 2001, 75: 213-218.
10. Romano M., Faggioni R., Sironi M., Sacco S., Echtenacher B., Di Santo E., Salmona M., Ghezzi P. Carraeanan-induced acute inflammation in the mouse air-pouch synovial model: role of tumour necrosis factor, *Mediators Inflamm.*, 1997, 6: 32-38.
11. Maleki N., Mohajel Nayebi A., Garjani A. Effects of central and peripheral depletion of serotonergic system on carrageenan-induced paw oedema, *International Immunopharmacology*, 2005, 5:1723-1730.
12. Michael B., Scott FK., Jeyaseelan SY., Lieber JG., Arndt PG., Nick JA., Worthen GS., A role for

-
- Hydroxy-Methylglutaryl Coenzyme A Reductase in pulmonary information and host defense, Am. J. Respiratory and Critical Care Medicine, 2005, 171: 606-615.
13. Cordle A., Koenigsknecht-Talboo J., Wilkinson B., Limpert A., Landreth G. Mechanisms of Statin-mediated Inhibition of Small G-protein Function, The Journal OF Biological Chemistry, 2005, 280(40): 34202-34209.
14. Schonbeck U., Libby P. Information, Immunity, and HMG-COA reductase inhibitors statins as anti-inflammatory agents?, Circulation, 2004, 109 [supple II]: II-18-II-26.
15. Diomede L., Albani D., Sottocorno M., Benedetta Donati M., Bianchi M., Fruscella P., Salmona M. In Vivo Anti Inflammatory Effect of Statins is mediated by Nonsterol Mevalonate Products, Arterioscler Thromb Vasc Biol., 2001, 21:1327-1332.

Archive of SID